v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (5,416,550) $ (4,333,949)
Adjustments to reconcile net loss to net cash used in operating activities    
Amortization of debt discount 258,891 605,630
Stock-based compensation 899,317 751,530
Changes in operating assets and liabilities:    
Accounts payable and accrued expenses 3,102,476 (1,481,113)
Accrued compensation 23,636 (282,518)
Due from Chromocell Corporation (45,786)
Prepaid expenses 52,959 (158,102)
Net Cash Used In Operating Activities (1,079,271) (4,944,308)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from loan payable, net of debt discount 625,000 1,455,416
Proceeds from loan payable, net of debt discount - related party 131,868
Payment of bridge loan, net of debt discount (214,757)
Common stock issued for cash 5,972,000
Recission of common stock (91,512)
Net Cash Provided By Financing Activities 625,000 7,253,015
NET CHANGE IN CASH (454,271) 2,308,707
CASH AT BEGINNING OF YEAR 513,443 96,391
CASH AT END OF YEAR 59,172 2,405,098
Supplemental cash flow information:    
Cash paid for income taxes
Cash paid for interest expense 18,750
NONCASH INVESTING AND FINANCING ACTIVITIES:    
Debt discount from common stock issued for extension of bridge loan 447,779
Conversion of notes to common stock 736,992 1,362,821
Transfer of liabilities to Chromocell Corporation for Series C Preferred Stock 2,153,362
Offering costs recorded to debt discount $ 39,063

Source

10-Q PDF XBRL Zip